General Callout
Nunc dolor esse suscipit eros eros ullamco dolor. Duis velaliquam sunt urna, tempuribud doming quis, laboris ultricies ultricies urna laboris. Nostrud pulvinar nostrud elit sunt ex exercitation magna tempuribud laboris ea ex nunc sed exercitation ea laboris dignissim.
Accordion
Quis harmud ea commodo voluptate dolor urna providerent tempor amet dignissim velit consectetur harmud sint doming, urna magna velit sed commodo urna sint sunt nunc. Nunc consectetur laboris harmud dolore exercitation sed magna laboris nulla velit velaliquam ultricies. Dignissim adipiscing, sed duis ultricies sint voluptate providerent nunc nisi.
Heading 1
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Heading 2
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Call to action
Esse suscipit in eros ea sed voluptate dolore, harmud nisi, dolore ultricies fugiat amet doming ut sint ut adipiscing. Sit velit velaliquam ex nunc ut voluptate
Vyzulta (latanoprostene bunod)
Status:
Concluded with an LOI
Manufacturer:
Bausch Health, Canada Inc.
Indication:
Open-angle Glaucoma
Last updated November 20, 2019
Status:
Concluded with an LOI
Manufacturer:
AstraZeneca Canada Inc.
Indication:
Non-Small Cell Lung Cancer (First-line, locally advanced or metastatic)
Last updated November 19, 2019
Status:
Concluded with an LOI
Manufacturer:
Bayer Inc.
Indication:
Prevention of stroke and cardiovascular events in coronary and peripheral artery disease.
Last updated November 15, 2019
Status:
Concluded with an LOI
Manufacturer:
Teva Canada Ltd.
Indication:
Early breast cancer, Metastatic breast cancer, Metastatic gastric cancer
Last updated November 13, 2019
Status:
Concluded with an LOI
Manufacturer:
Eisai Limited
Indication:
Hepatocellular Carcinoma (HCC) in adults after prior therapy
Last updated November 8, 2019
Status:
Concluded with an LOI
Manufacturer:
Ipsen Biopharmaceuticals Canada, Inc.
Indication:
Renal Cell Carcinoma
Last updated November 5, 2019
Iluvien (fluocinolone acetonide)
Status:
Negotiations were not pursued
Manufacturer:
Knight Therapeutics Inc.
Indication:
Diabetic Macular Edema
Last updated November 1, 2019
Status:
Concluded without agreement
Manufacturer:
Hoffmann-La Roche Ltd.
Indication:
Breast Cancer
Last updated October 29, 2019
Venclexta/rituximab (venetoclax/rituximab)
Status:
Concluded with an LOI
Manufacturer:
AbbVie Corporation
Indication:
In combination with rituximab (V+R) is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy
Last updated October 28, 2019
Lonsurf (trifluridine/tipiracil)
Status:
Negotiations were not pursued
Manufacturer:
Taiho Pharma Canada Inc.
Indication:
Metastatic Colorectal Cancer
Last updated October 18, 2019